Synlogic, Inc.
Synlogic, Inc. is a U.S.-based biopharmaceutical company organized around engineered bacterial therapeutics and related research programs. The company was originally built to develop treatments for rare metabolic disorders and operates through Synlogic, Inc. and its subsidiaries from the United States.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaDrug candidates and platform programs aimed at treating rare metabolic diseases.
Non-product arrangements such as material transfer and consulting work.
Asiakkaat
Synlogic's direct customers have historically been collaboration partners, research counterparties, and other strategic transaction counterparties rather than commercial patients or hospitals. Its therapeutic programs are aimed at patients with rare metabolic disorders such as phenylketonuria and homocystinuria, but the company has not operated a commercial product business.
Companies or investors evaluating a merger, sale, or other strategic transaction.
Partners that may license, fund, or co-develop therapeutic assets or platform capabilities.
Counterparties purchasing limited scientific or consulting services under non-product agreements.
The intended end users of the company's metabolic disorder programs, especially PKU and HCU.
Strategia
The company's stated strategy is centered on pursuing strategic alternatives to enhance stockholder value, including a merger, sale, or other transaction. Operationally, it has substantially reduced its internal footprint and relies on a very small team and consultants while it evaluates transaction opportunities.
The company is focused on maximizing value through a merger, sale, or similar deal.
A lean structure helps extend runway while alternatives are evaluated.
Any transaction value depends on the remaining technology, patents, and know-how.
Maantiede
Synlogic is headquartered in the United States and its corporate, research, and administrative activities have been centered there. Its disclosed development work has included global clinical study activity, but the company does not report a broad commercial manufacturing or sales footprint.
Riskit
Synlogic faces high execution risk because it is a non-operating shell company with no commercial product revenue and a very limited operating base. Its securities have been delisted from Nasdaq, and the outcome of any strategic transaction is uncertain, which can materially affect liquidity, valuation, and shareholder outcomes.
- Nasdaq delisting and OTC tradingVaikutus: KorkeaTodennäköisyys: Korkea
Reduced exchange access can lower liquidity, coverage, and financing flexibility.
Kohdistuu: Common stock trading and capital raising
- Non-operating shell company statusVaikutus: KorkeaTodennäköisyys: Korkea
The company has substantially wound down operations, limiting standalone business prospects.
Kohdistuu: Corporate valuation and transaction optionality
- Strategic transaction uncertaintyVaikutus: KorkeaTodennäköisyys: Korkea
A merger or sale may not be completed or may not deliver expected value.
Kohdistuu: Stockholder value realization
- Biopharmaceutical development failureVaikutus: KeskitasoTodennäköisyys: Korkea
Clinical and regulatory outcomes are inherently uncertain and capital intensive.
Kohdistuu: Legacy therapeutic assets and IP value
- Key-person and operating concentrationVaikutus: KeskitasoTodennäköisyys: Matala
A very small team makes the company dependent on a few individuals and advisors.
Kohdistuu: Corporate continuity and transaction execution
Kirjanpito
Harkinnanvaraiset erätChanges in valuation can create large non-cash gains or losses in earnings.
Vaikutus: Affects other income/expense and net loss
Wind-down costs and severance-related items can distort period comparability.
Vaikutus: Affects operating expenses and reported loss
Historical collaboration revenue is limited and no product revenue is expected.
Vaikutus: Affects comparability of legacy collaboration periods
Clinical and research spending was previously a major cost area, but is now reduced.
Vaikutus: Affects operating expense trend analysis
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Rezolute, Inc.
RZLT · Pharmaceutical Preparations
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Rallybio Corp
RLYB · Pharmaceutical Preparations
Rallybio Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for rare diseases with significant unmet medical need.
Soligenix, Inc
SNGX · Pharmaceutical Preparations
MediciNova, Inc
MNOV · Pharmaceutical Preparations
MedicNova Inc.
Moolec Science SA
MLECW · Food and Kindred Products
Moolec Science SA is a U.S.-based food technology company that engineers plants and microbes to produce proteins, lipids, enzymes, and other biomolecules for the food and agriculture value chain.
Päivitetty: 24.9.2026